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UTILIZATION REVIEW OF SSRI THERAPY AT
A MENTAL HEALTH MANAGED CARE
ORGANIZATION.
Conner TM, Rascati KL, Crawford KM
University of Texas at Austin, Austin, TX, USA
In an era of cost containment, psychiatric drug formular-
ies often limit choice of first-line selective serotonin re-
uptake inhibitors (SSRI) in the treatment of depression.
OBJECTIVES: Most patients in this study belong to one
of three managed care systems with varying drug formu-
laries. The purpose of this study was to describe treat-
ment events and utilization of services by patients with
depression initially prescribed one of three SSRIs in a
"treatment as usual" setting.
METHODS: Patients with major depression were identi-
fied in the organization database. Retrospective chart re-
views determined patient demographics, frequency of ad-
verse events, attrition rate, and utilization of services over
a six-month period following initiation of therapy.
RESULTS: One-hundred forty charts were reviewed. SSRIs
were equally prescribed. The mean age of patients was
39.5, (sd = 14.1). Approximately 38% were Hispanic.
Approximately 41 % had prior SSRI therapy. Prescribers
tended to follow restricted formularies but showed no
preference with an open formulary. Chi-square analyses
revealed that among the SSRIs, there was no difference in
attrition or in reports that patients had at least one ad-
verse effect. On average, patients received 2.3 prescriber
visits during the initial six months of therapy, with no
significant difference by SSRI.
CONCLUSIONS: Preliminary evidence suggests no dif-
ference in the number of outpatient prescriber visits, at-
trition rates, or reports of at least one adverse effect
among the three SSRIs. Further analysis will examine fre-
quency of patients who switched from initial SSRI to an-
other antidepressant. The results of this study are limited
by small sample size, non-randomization of patients, and
data derived from documentation in medical records. Fu-
ture research will prospectively measure symptomatology
of depression, along with utilization of services and treat-
ment events.
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TEXAS MEDICATION ALGORITHM PROJECT:
FEASIBILITY STUDY OF IMPLEMENTING
MEDICATION ALGORITHMS IN THE PUBLIC
MENTAL HEALTH SECTOR
Crismon ML', Rush AJ', Toprac MG2,Shon S2, Biggs MM',
Shores-Wilson K', Mason M2
IUniversity of Texas at Austin, College of Pharmacy, Austin,
TX, USA; 2Texas Department of Mental Health and Mental
Retardation, Austin, TX, USA
OBJECTIVE: The aim of this study was to determine the
feasibility and suitability of implementing consensually
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derived, evidence based, medication algorithms in the
care of patients treated in the public mental health sector.
METHODS: Each of 40 physicians at 16 sites treated 5-
15 patients for up to 4 months with one of the algorithms
(schizophrenia [SCZj, bipolar disorder [BPDj, or major
depressive disorder [MDDj). Process measures included
visit frequency, staff time, algorithm stages used, time on
treatment stage, and medications used. Outcome mea-
sures included the Brief Psychiatric Rating Scale (BPRS),
Inventory of Depressive Symptoms (IDS), Clinical Global
Impression (CGI), and the Multnomah Community Abili-
ties Scale (MCAS).
RESULTS: 222 patients entered the study. Survival rate
at 90 days was 75%. Physician time was approximately
40 minutes at the initial visit and 30 minutes at follow-up
visits; visits were approximately 3 weeks apart. 52% of
patients with SCZ and 55% of patients with BPD had
>30% decrease in BPRS score. 38% of patients with
MDD had >50% decrease in IDS score. All patient
groups except outpatient SCZ had significant improve-
ment on the MCAS. Physician satisfaction was high with
nearly 80% of the physicians stating that they would con-
tinue using the algorithms.
CONCLUSIONS: Medication algorithms were imple-
mented in the population and in general were associated
with good improvement in patient symptoms and func-
tion. Major obstacles to widespread implementation are
adequate staffing, staff support, and availability of cer-
tain medications. Clinical and economic impact of the al-
gorithms are currently being evaluated in a comparative
study.
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DEVELOPING A TASK-BASED INSTRUMENT TO
MEASURE MIGRAINE-RELATED PRODUCTIVITY
Lee TAt, Ramsey S02.3, Neil NJ', Patrick OL3, Klastorin T04,
Stergachis AU, and Sullivan SO,,3
University of Washington, Schools of I Pharmacy, 2Medicine,
'Public Health and Community Medicine, 4Business
Administration, Seattle, WA, USA
Migraine headache is a severe and debilitating disease
that is estimated to affect 4 out of 100 Americans. The
nature of migraine attacks and the variability in their oc-
currence have substantial economic implications.
OBJECTIVE: The purpose of this project is to develop a
multi-item, task-based instrument to measure the impact
of migraine on several domains. The domains include
workplace productivity, housekeeping, and impact on lei-
sure activities.
METHODS: An extensive review of the literature was
performed to determine methods of assessing migraine-
related productivity. Current instruments used in the
measurement of disease-related productivity were re-
viewed for content. Focus groups were held to determine
important productivity-related issues to migraineurs. The
groups consisted of migraineurs (n = 12) recruited by a
research organization and screened with an instrument
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based on criteria from the Headache Classification Com-
mittee of the International Headache Society. The focus
group meetings consisted of scripted questions that were
both directed and open-ended. The questions addressed
issues relevant to the domains of interest and how they
are impacted by migraines.
RESULTS: The information acquired in the focus groups
was used to develop an 81-item questionnaire with four
open-ended questions and 77 directed questions. The di-
rected questions are scored on a Likert-type scale ranging
from "never when I have a migraine" to "every time I
have a migraine." The content of the instrument ranges
from missing work to taking longer breaks or missing
deadlines.
CONCLUSION: A first-line instrument was developed to
assess migraine-related productivity. The instrument will
next be tested for validity and analyzed for item reduction.
SCHIZOPHRENIA MANAGEMENT: DOES
MANAGED CARE INFLUENCE LENGTH
OF STAY IN U.S. HOSPITALS?
O'Brien JA, Pietrusewicz MJ, Pierce D, Caro JJ
Caro Research, Boston, MA, USA
Insurers' influence on patterns of care and disease man-
agement continues to be questioned in the u.s.
OBJECTIVE: To determine the effect managed care has
on length of stay (LOS) and costs of inpatient manage-
ment of schizophrenia in acute general hospitals.
METHODS: LOS and cost estimates were developed
based on patient-level data from the 1996 Massachusetts
discharge database. Analyses were limited to patients with
a principal diagnosis of schizophrenia (based on ICD9
codes). Three populations were examined: an all payer
group, a standard Medicaid coverage group, and those
with a Medicaid-funded managed care plan (MMC).
Unique patient identifiers enabled examination of annual
admission frequency. All costs are reported in 1996 US$,
adjusted appropriately for cost-to-charge ratios.
RESULTS: Of the 3,500 patients admitted for schizo-
phrenia, 582 (17%) were covered by Medicaid and 419
(12%) by MMC. Overall, patients were admitted an av-
erage of 1.7 times in the year, with 67% having only one
admission. The mean admission rate was 1.8 among
Medicaid patients and 1.6 with MMC; a single admission
occurred in 73% of the Medicaid group and 67% for
MMC. The mean LOS was 14 days for the Medicaid
group compared to 13.5 days for the all payer group and
12.3 days for those with MMC. Among those with only
one admission, the difference increases: 16.4 days for the
Medicaid group, 14.7 days for the all payer group, and
12.9 for the MMC group. Costs for this admission were
correspondingly highest for standard Medicaid ($10,864)
and lowest for MMC ($7,911).
CONCLUSION: The managed care approach decreases
the length of stay and cost of inpatient management of
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schizophrenia. The appropriateness of these reductions
remains unclear.
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DEVELOPMENT OF A SELF-ADMINISTERED
OUTCOME MEASURE FOR USE IN AN
OUTPATIENT POPULATION OF INDIVIDUALS
WITH SCHIZOPHRENIA
Barr JT, Schumacher GE, Mason EJ, Ohman SM, Hanson A
Northeastem University, Boston, MA, USA; Massachusetts
Division of Medical Assistance, Boston, MA, USA
OBJECTIVE: We developed a self-administered, health
status measure to monitor and assess the functional sta-
tus and response to treatment in an outpatient population
of individuals with schizophrenia.
METHODS: 442 adult consumers with schizophrenia
(61% male, 39% female) were recruited from >50 sites
in the Massachusetts mental health system. Consumers
completed 7 administrations of a set of 2 assessment mea-
sures over a 9-month period: a 75-item prototype ques-
tionnaire used to sample subjective and objective con-
sumer and the BASIS-32, a 32-item mental health status
measure. Several staff assessments of consumer status
were also completed at each administration.
RESULTS: The original consumer battery of 107 items
was reduced and modified to 46 using correlation, vari-
ance, item, and factor analyses. The 7 constructs com-
prising the 46 items included-in decreasing order of
contribution to the total variance of the factor analysis-
mental health, work and leisure, self-concept, activities of
daily living, physical function, interpersonal satisfaction,
and medication effects. These 7 constructs explained
63% of the variance, with Cronbach's alpha of 0.94.
Test-retest reliability was approximately 0.8. Item to to-
tal score correlations were all significant and ranged from
0.24 to 0.68. The above set of 46 items was then aug-
mented by 5 additional items gleaned from consumer and
expert panel assessments of item importance to yield a
51-item instrument called the Health Status-S Survey.
CONCLUSION: The Health Status-S Survey appears
practical in a community-based population of individuals
with schizophrenia. The survey is now being validated in
5 states-Arizona, Massachusetts, South Carolina, Wash-
ington, and Wisconsin-using 4 administrations over 3
months for 300 consumers per state.
